A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

GU Research Network, LLC

Status and phase: Withdrawn; Phase 2

Conditions: Non-small Cell Lung Cancer (NSCLC)

Treatments: Drug: Cisplatin; Drug: Abraxane; Biological: AGS-003-LNG; Drug: Taxol; Drug: Carboplatin; Radiation: Radiation Therapy; Drug: Alimta

Study type: Interventional

Funder types: Other

Identifiers

NCT02662634

AGS-003-024

Details and patient eligibility

About

Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.

Full description

Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer. Non-small cell lung cancer tumor will be resected from the patient. RNA from the tumor will be amplified and subsequently electroporated into matured, autologous dendritic cells. The dendritic cells with tumor RNA will be dosed back to the patient. Study will investigate feasibility and safety.

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥ 19 years.
2. Newly diagnosed non-small cell lung cancer indicated for routine lobectomy, mediastinoscopy, wedge resection, thoracotomy or Video-assisted thoracoscopic surgery (VATS) procedures with tumor collection.
3. Stage III (T1-3, N1-2, M0) of any histology.
4. Scheduled for routine lobectomy, mediastinoscopy, wedge resection, thoracotomy or VATS procedures.
5. Signed and dated informed consent document for study participation.

After tumor collection, potential subjects must meet all the following criteria to be enrolled in study treatment:

1. Successful RNA isolation and amplification from tumor sample (as determined by Argos).
2. Karnofsky performance status (KPS) score of 80-100.
3. Life expectancy of six months or greater.
4. NSCLC of any histology.
5. Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade ≤ 1 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
6. Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug.
7. Able to abstain from taking prohibited drugs, either prescription or non-prescription, during the treatment phase of the study.
8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
9. Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment.

Exclusion criteria

1. Active autoimmune disease or condition requiring chronic immunosuppressive therapy

2. Any clinically significant condition that prohibits the initiation of standard of care.

3. Malignancies within the prior three years, except for:

   • treated in situ carcinomas or non-melanoma skin cancer.
   • adequately treated early stage breast cancer.
   • superficial bladder cancer.
   • non-metastatic prostate cancer with a normal prostate-specific antigen (PSA) level.

4. History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease.

5. Clinically significant disorders or conditions including

   • cardiovascular system.
   • renal system.
   • hepatic organ system.
   • coagulation disorders.

6. Clinically significant infections, including human immunodeficiency virus (HIV), syphilis, and active hepatitis B or C.

7. Pregnant or breastfeeding.

8. Any serious medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational treatment.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 4 patient groups

Sequential, no radiation

Experimental group

Description:

AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI Carboplatin/Abraxane: ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin Area Under Curve (AUC) 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE. Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA. Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA. Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G).

Treatment:

Drug: Alimta

Radiation: Radiation Therapy

Drug: Carboplatin

Drug: Taxol

Drug: Abraxane

Drug: Cisplatin

Biological: AGS-003-LNG

Concurrent, no radiation

Experimental group

Description:

AGS-003-LNG dosing initiated concurrently or subsequent to 3rd cycle of platinum doublet chemotherapy \& radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses will then be administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells. Platinum-doublet chemotherapy can be any of the following determined by PI Carboplatin/Abraxane: ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin AUC 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE. Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA. Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA. Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G).

Treatment:

Drug: Alimta

Radiation: Radiation Therapy

Drug: Carboplatin

Drug: Taxol

Drug: Abraxane

Drug: Cisplatin

Biological: AGS-003-LNG

Sequential, radiation

Experimental group

Description:

AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI Carboplatin/Abraxane: ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin AUC 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE. Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA. Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA. Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G). Radiation therapy per PI

Treatment:

Drug: Alimta

Radiation: Radiation Therapy

Drug: Carboplatin

Drug: Taxol

Drug: Abraxane

Drug: Cisplatin

Biological: AGS-003-LNG

Concurrent, radiation

Experimental group

Description:

AGS-003-LNG dosing initiated concurrently during or subsequent to the 3rd cycle (3-week cycle) of platinum doublet chemotherapy \& radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells. Platinum-doublet chemotherapy choice of the following determined by PI Carboplatin/Abraxane: ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, \& 15 of each 21-day cycle; carboplatin AUC 6 (C\&G) on Day 1 of each 21-day cycle immediately after ABRAXANE. Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C\&G) i.v. 30 minutes after ALIMTA. Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA. Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C\&G). Radiation therapy per PI.

Treatment:

Drug: Alimta

Radiation: Radiation Therapy

Drug: Carboplatin

Drug: Taxol

Drug: Abraxane

Drug: Cisplatin

Biological: AGS-003-LNG